Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IBO vs ENTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
IBO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)
IBO Overall Winner
6-Pillar Tally: IBO 4 – 1 ENTX (1 Tie)
Matrix Metrics: IBO 5 – 4 ENTX
As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Entera Bio Ltd. (ENTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas ENTX carries 48.1/100 (HOLD) at $3.04 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While ENTX currently prints a higher short-term Unified Composite Score (48.1/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. -100.0% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About IBO vs ENTX
IBO
Head-to-Head Winner
Impact BioMedical, Inc.
$4.96
-3.5% 1D
Market Cap
$41.2M
TTM Revenue
$2.3M
Forward P/E
N/M
Beta / 30D Vol
-6.75β · 120% Vol
Unified Composite Score
36.8
SELL
Tech 15.0
Fund 32.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
ENTX
Entera Bio Ltd. Ordinary Shares
$3.04
-2.25% 1D
Market Cap
$560.7M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.07β · 46% Vol
Unified Composite Score
48.1
HOLD
Tech 34.0
Fund 51.0
Flow 76.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (IBO 4 – 1 ENTX)
1. Valuation Multiples
IBO
Forward P/E
N/M
N/M
Trailing P/E
0.4x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
18.2x
N/M
2. Growth & Scale
IBO
Revenue Growth (YoY)
+16.7%
-100.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$2.3M
N/A
Market Cap
$41.2M
$560.7M
3. Profitability & Quality
IBO
Gross Margin
N/A
N/A
Operating Margin
-12621.0%
0.0%
Net Profit Margin
4247.4%
0.0%
Return on Equity (ROE)
71.2%
-138.9%
4. Balance Sheet & Cash Flow
IBO
Cash Generation (TTM)
-$99M
-$16M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$1.18 Book/Sh · 71.2% ROE
$265M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ENTX
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
164.0% (47th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
High-Margin Pricing Power Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: IBO (5) vs ENTX (4)| Institutional Metric | IBO | ENTX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $41.2M | $560.7M | ENTX | |
| Trailing P/E Ratio | 0.4x | N/M | IBO | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +16.7% | -100.0% | IBO | |
| Operating Margin (TTM) | -12621.0% | 0.0% | ENTX | |
| Net Profit Margin | 4247.4% | 0.0% | IBO | |
| Return on Equity (ROE) | 71.2% | -138.9% | IBO | |
| 52-Week Range Position | 68% ($0–$7) | 65% ($1–$4) | IBO | |
| Beta / 30D Volatility | -6.75β · 120% Vol | 1.07β · 46% Vol | ENTX | |
| Unified Institutional Score | 36.8 / 100 (SELL) | 48.1 / 100 (HOLD) | ENTX | |
| Trailing 12M Revenue (USD) | $2.3M | N/A | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 18.2x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$99M ($1.18 Book/Sh · 71.2% ROE) | -$16M ($265M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
IBO +71.64 pp
3M Horizon
IBO +950.13 pp
6M Horizon
IBO +674.27 pp
1Y Horizon
IBO +861.6 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | IBO Revenue | ENTX Revenue | IBO Op. Margin | ENTX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | N/A | $0M | N/A | -3059.7% | ENTX |
| FY2021 | N/A | $0M | N/A | -2139.6% | ENTX |
| FY2022 | $0M | $0M | -6808.0% | -9714.2% | IBO |
| FY2024 | N/A | $0M | N/A | -5295.6% | ENTX |
| FY2025 | $0M | $0M | -13381.2% | -27450.0% | IBO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
IBO
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ENTX
CONSOLIDATION
Current IV
164.0%
IV Percentile
47th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
IBO Moat Profile
High-Margin Pricing Power Moat
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ENTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ IBO vs ENTX Key Questions & Quantitative Answers
As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Entera Bio Ltd. (ENTX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas ENTX carries 48.1/100 (HOLD) at $3.04 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ENTX currently prints a higher short-term Unified Composite Score (48.1/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. -100.0% YoY).
IBO leads the Growth & Scale pillar: IBO posts +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (N/A gross margin, -12621.0% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 5-period historical trajectory (FY2020 to FY2025), IBO cumulative revenue shifted N/A while ENTX shifted N/A. In operating R&D and SG&A reinvestment, IBO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.
IBO screens cheaper on headline valuation multiples. IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 18.2x EV/Revenue (unreported FCF margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBO (71.2% ROE) versus ENTX (-138.9% ROE) capital efficiency.
In options market volatility and institutional positioning, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.75β · 120% Vol realized risk). By comparison, ENTX carries 164.0% implied volatility (47th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 46% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ENTX vs IBO · Reverse Pair
IBO vs PLRZ
· Sector Peer
ENTX vs IMMP
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal